{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:28:07Z","timestamp":1771514887114,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In this Debate, based on our clinical data from the \u201cpre-nirsevimab\u201d and \u201cfirst year of nirsevimab implementation\u201d bronchiolitis seasons, we challenge the validity of policy decisions that led to partial immunization coverage of eligible newborns and infants during the 2024\u201325 season in Italy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>Starting with a pre-nirsevimab prospective cohort of 780 newborns, we documented that 84 (9.2%) were diagnosed with acute bronchiolitis (45 of them (5.8% of the cohort) were RSV positive. 44 patients (5.6%) were hospitalized due to bronchiolitis, of which 7 (0.9%) patients were admitted to the Pediatric Intensive Care Unit. Among hospitalized, 31 infants (70%) had RSV infection. Secondly, we evaluated the impact on bronchiolitis admissions during the first year of nirsevimab use in our region, showing a negligible effect on the most severe cases, probably due to the fact that a low coverage will risk to miss the relatively small number of infants (about 10%) that will develop RSV bronchiolitis in the first year of life. These findings inspired our clinical insights and reflections arguing that without a long-term, cost-conscious approach to implementation, even major scientific breakthroughs like nirsevimab risk becoming public health failures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our clinical insights and reflections aim to inspire deeper engagement among policymakers, health agencies, and clinicians to better adapt and integrate RSV preventive strategies\u2014maximizing benefit not only for susceptible infants, but for society at large. In a world of finite healthcare resources, optimizing both the reach and the value of such essential interventions is imperative, given the multitude and diversity of health needs our society is facing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13052-025-02147-9","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:08:08Z","timestamp":1763136488000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["How a major discovery can become a public health failure when used subotptimally: lessons from early nirsevimab implementation"],"prefix":"10.1186","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8567-2639","authenticated-orcid":false,"given":"Danilo","family":"Buonsenso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Perramon-Malavez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Morello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Gentili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Bellorofonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Soriano-Arandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"10","key":"2147_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/jpc.16643","volume":"60","author":"MWC Loe","year":"2024","unstructured":"Loe MWC, Soenong H, Lee E, Li-Kim-Moy J, Williams PC, Yeo KT, Nirsevimab. Alleviating the burden of RSV morbidity in young children. J Paediatr Child Health. 2024;60(10):489\u201398. https:\/\/doi.org\/10.1111\/jpc.16643. Epub 2024 Aug 16. PMID: 39150043.","journal-title":"J Paediatr Child Health"},{"issue":"1","key":"2147_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-022-01392-6","volume":"49","author":"S Manti","year":"2023","unstructured":"Manti S, Staiano A, Orfeo L, Midulla F, Marseglia GL, Ghizzi C, et al. Update \u2013\u20092022 Italian guidelines on the management of bronchiolitis in infants. Ital J Pediatr. 2023;49(1):19. https:\/\/doi.org\/10.1186\/s13052-022-01392-6.","journal-title":"Ital J Pediatr"},{"key":"2147_CR3","unstructured":"https:\/\/www.cdc.gov\/rsv\/infants-youngchildren\/index.html#:~:text=Each%20year%20in%20the%20United,age%2C%20the%20higher%20the%20risk)."},{"key":"2147_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0296685","volume":"19","author":"A Shiroshita","year":"2024","unstructured":"Shiroshita A, Gebretsadik T, Wu P, Kubilay NZ, Hartert TV. Association between age of respiratory syncytial virus infection hospitalization and childhood asthma: a systematic review. PLoS ONE. 2024;19:e0296685. https:\/\/doi.org\/10.1371\/journal.pone.0296685.","journal-title":"PLoS ONE"},{"key":"2147_CR5","unstructured":"Influnet stagione influenzale 2022\/2023. Incidenza delle sindromi simil-influenzali in Italia per fascia di et\u00e0 - Settimane 42\/2022\u201317\/2023. https:\/\/www.quotidianosanita.it\/allegati\/allegato1683365649.pdf. Accessed 24 Nov 2023."},{"issue":"1","key":"2147_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-024-01617-w","volume":"50","author":"F Fortunato","year":"2024","unstructured":"Fortunato F, Campanozzi A, Maffei G, Arena F, Carri VD, Rollo T, et al. Respiratory syncytial virus-associated hospitalizations among children: an Italian retrospective observational study. Ital J Pediatr. 2024;50(1):45. https:\/\/doi.org\/10.1186\/s13052-024-01617-w.","journal-title":"Ital J Pediatr"},{"issue":"01","key":"2147_CR7","doi-asserted-by":"publisher","first-page":"e1107","DOI":"10.1055\/a-1990-2633","volume":"41","author":"T Gonzales","year":"2024","unstructured":"Gonzales T, Bergamasco A, Cristarella T, Goyer C, Wojdyla M, Oladapo A, Sawicky J, Yee J, Moride Y. Effectiveness and safety of Palivizumab for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus: A systematic review. Am J Perinatol. 2024;41(01):e1107\u201315. https:\/\/doi.org\/10.1055\/a-1990-2633. Epub 2022 Nov 30. PMID: 36452969; PMCID: PMC11108679.","journal-title":"Am J Perinatol"},{"issue":"1","key":"2147_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40057-8","volume":"14","author":"B Ahani","year":"2023","unstructured":"Ahani B, Tuffy KM, Aksyuk AA, Wilkins D, Abram ME, Dagan R, et al. Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials. Nat Commun. 2023;14(1):4347. https:\/\/doi.org\/10.1038\/s41467-023-40057-8.","journal-title":"Nat Commun"},{"key":"2147_CR9","unstructured":"https:\/\/www.aifa.gov.it\/documents\/20142\/1805944\/DETERMINA_9-2023_BEYFORTUS.pdf"},{"issue":"2","key":"2147_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pedneo.2023.04.015","volume":"65","author":"T Yu","year":"2024","unstructured":"Yu T, Padula WV, Yieh L, Gong CL. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29\u201334 6\/7 weeks\u2019 gestation in the United States. Pediatr Neonatol. 2024;65(2):152\u20138. https:\/\/doi.org\/10.1016\/j.pedneo.2023.04.015.","journal-title":"Pediatr Neonatol"},{"key":"2147_CR11","doi-asserted-by":"publisher","DOI":"10.1055\/a-2531-0968","author":"A Soriano-Arandes","year":"2025","unstructured":"Soriano-Arandes A, Creus-Costa A, Perramon-Malavez A, Andr\u00e9s C, Vila J, Gatell A, et al. Early experience on universal prophylaxis in infants against respiratory syncytial virus: facts and expectations. Semin Respir Crit Care Med. 2025. https:\/\/doi.org\/10.1055\/a-2531-0968.","journal-title":"Semin Respir Crit Care Med"},{"issue":"16","key":"2147_CR12","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann B, Madhi SA, Munjal I, Sim\u00f5es EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2216480.","journal-title":"N Engl J Med"},{"key":"2147_CR13","unstructured":"Regione Lazio Registro Ufficiale U. 1020755.13-08-2024."},{"key":"2147_CR14","unstructured":"https:\/\/www.statoregioni.it\/media\/lhnb3llv\/p-fs-csr-atto-rep-n-188-17ott2024.pdf"},{"key":"2147_CR15","unstructured":"https:\/\/pro.campus.sanofi\/dam\/Portal\/Italy\/resources\/vaccines\/La-prima-stagione-di-nirsevimab-in-italia\/Pubblicazione---La-prima-stagione-di-nirsevimab-in-Italia.pdf."},{"issue":"5","key":"2147_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11050416","volume":"11","author":"N Suleiman-Martos","year":"2021","unstructured":"Suleiman-Martos N, Caballero-V\u00e1zquez A, G\u00f3mez-Urquiza JL, Albend\u00edn-Garc\u00eda L, Romero-B\u00e9jar JL, Ca\u00f1adas-De La Fuente GA. Prevalence and risk factors of respiratory syncytial virus in children under 5 years of age in the WHO European region: a systematic review and meta-analysis. J Pers Med. 2021;11(5):416. https:\/\/doi.org\/10.3390\/jpm11050416.","journal-title":"J Pers Med"},{"key":"2147_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1173842","volume":"14","author":"MVM Divarathna","year":"2023","unstructured":"Divarathna MVM, Rafeek RAM, Morel AJ, Aththanayake C, Noordeen F. Epidemiology and risk factors of respiratory syncytial virus associated acute respiratory tract infection in hospitalized children younger than 5 years from Sri Lanka. Front Microbiol. 2023;14:1173842. https:\/\/doi.org\/10.3389\/fmicb.2023.1173842.","journal-title":"Front Microbiol"},{"issue":"2","key":"2147_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1056\/NEJMoa2314885","volume":"391","author":"Z Assad","year":"2024","unstructured":"Assad Z, Romain AS, Aupiais C, Shum M, Schrimpf C, Lorrot M, et al. Nirsevimab and hospitalization for RSV bronchiolitis. N Engl J Med. 2024;391(2):144\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2314885.","journal-title":"N Engl J Med"},{"key":"2147_CR19","doi-asserted-by":"publisher","unstructured":"Ares-G\u00f3mez S, Mallah N, Santiago-P\u00e9rez MI, Pardo-Seco J, P\u00e9rez-Mart\u00ednez O, Otero-Barr\u00f3s MT, Su\u00e1rez-Gaiche N, Kramer R, Jin J, Platero-Alonso L, Alv\u00e1rez-Gil RM, Ces-Ozores OM, Nartallo-Penas V, Mir\u00e1s-Carballal S, Pi\u00f1eiro-Sotelo M, Malvar-Pintos A, Gonz\u00e1lez-P\u00e9rez JM, Rodr\u00edguez-Tenreiro-S\u00e1nchez C, Rivero-Calle I, Salas A, Dur\u00e1n-Parrondo C, Martin\u00f3n-Torres F, NIRSE-GAL study group. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis. 2024;24(8):817\u2013828. https:\/\/doi.org\/10.1016\/S1473-3099(24)00215-9 . Epub 2024 Apr 30. Erratum in: Lancet Infect Dis. 2024;24(7):e419. https:\/\/doi.org\/10.1016\/S1473-3099(24)00355-4. PMID: 38701823.","DOI":"10.1016\/S1473-3099(24)00215-9"},{"issue":"5","key":"2147_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12050549","volume":"12","author":"A Consolati","year":"2024","unstructured":"Consolati A, Farinelli M, Serravalle P, Rollandin C, Apprato L, Esposito S, et al. Safety and efficacy of nirsevimab in a universal prevention program of respiratory syncytial virus bronchiolitis in newborns and infants in the first year of life in the Valle d\u2019Aosta Region, Italy, in the 2023\u20132024 epidemic season. Vaccines. 2024;12(5):549. https:\/\/doi.org\/10.3390\/vaccines12050549.","journal-title":"Vaccines"},{"issue":"9","key":"2147_CR21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2110275.","journal-title":"N Engl J Med"},{"key":"2147_CR22","unstructured":"https:\/\/sip.it\/2025\/03\/27\/vrs-protezione-a-macchia-di-leopardo-e-i-bambini-non-sono-tutti-uguali\/."},{"issue":"6","key":"2147_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/children10061081","volume":"10","author":"A Camporesi","year":"2023","unstructured":"Camporesi A, Morello R, Pierucci UM, Proli F, Lazzareschi I, Bersani G, et al. 2021\/22 and 2022\/23 post-pandemic bronchiolitis seasons in two major Italian cities: a prospective study. Children (Basel). 2023;10(6):1081. https:\/\/doi.org\/10.3390\/children10061081.","journal-title":"Children (Basel)"},{"key":"2147_CR24","unstructured":"https:\/\/www.salutelazio.it\/documents\/10182\/23074243\/Allegato+1\/01ffff45-43c4-66e4-dcf7-2c9116912c8d."},{"key":"2147_CR25","unstructured":"Epidemiologisches Bulletin, Aktuelle Daten Und Informationen Zu Infektionskrankheiten Und, Public Health. Stiko. Prophylaxe von RSV-Erkrankungen Mit nirsevimab Bei Neugeborenen und S\u00e4ugling. Volume 26. Robert Koch Institut; 2024. p. 27. Juni 2024."},{"key":"2147_CR26","unstructured":"https:\/\/www.simri.it\/wp-content\/uploads\/2024\/12\/302.pdf."},{"key":"2147_CR27","doi-asserted-by":"publisher","first-page":"107268","DOI":"10.1016\/j.ijid.2024.107268","volume":"149","author":"X Yu","year":"2024","unstructured":"Yu X, Wang H, Ma S, Chen W, Sun L, Zou Z. Estimating the global and regional burden of lower respiratory infections attributable to leading pathogens and the protective effectiveness of immunization programs. Int J Infect Dis. 2024;149:107268. Epub 2024 Oct 15. PMID: 39413960.","journal-title":"Int J Infect Dis"},{"issue":"16","key":"2147_CR28","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2216480.","journal-title":"N Engl J Med"},{"key":"2147_CR29","unstructured":"https:\/\/www.gov.uk\/government\/publications\/respiratory-syncytial-virus-rsv-vaccination-programmes-letter\/introduction-of-new-nhs-vaccination-programmes-against-respiratory-syncytial-virus-rsv"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-025-02147-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-025-02147-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-025-02147-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T01:04:30Z","timestamp":1763168670000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-025-02147-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2147"],"URL":"https:\/\/doi.org\/10.1186\/s13052-025-02147-9","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective observational study involving human participants followed the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study is a subanalysis of a larger European multicenter study assessing changes in bronchiolitis in Europe before and after the beginning of the pandemic (Comitato Etico Fondazione Policlinico Universitario A. Gemelli IRCCS ID 3497, Prot 0049226\/20, 02\/10\/2020). Consent was not required at any site for these aggregated, population level datasets.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"RM and DB has participated to trials for Nirsevimab in healthy late preterm and term infants as a sub investigator.The rest of the authors have nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"301"}}